

MedMira Inc.

Condensed Interim Consolidated Financial Statements
For the nine months ended April 30, 2025 and April 30, 2024
(Unaudited – Prepared by Management)

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the period ending April 30, 2025.

June 30, 2025

Management's responsibility for financial reporting

The accompanying consolidated financial statements of MedMira Inc. (MedMira or the Company) are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards (IFRS). The consolidated financial statements include amounts and assumptions based on management's best estimates which have been derived with careful judgement.

In fulfilling its responsibilities, management has developed and maintains a system of internal accounting controls. These controls are designed to ensure that the financial records are reliable for preparation of the consolidated financial statements.

The Board of Directors of the Company is responsible for ensuring that management fulfils its responsibilities for financial reporting and is ultimately responsible for reviewing and approving the condensed interim consolidated financial statements and the accompanying management's discussion and analysis. The Board of Directors carries out this responsibility principally through its Audit Committee.

The Audit Committee is a subcommittee of the Board of Directors. It is responsible for oversight of the internal control and financial matters assisting the Company's management and independent auditors to ensure that the integrity of the financial reporting process is maintained.

(signed) *Hermes Chan*
Chief Executive Officer

(signed) *Markus Meile*
Chief Financial Officer

Unaudited consolidated statements of financial position

As at April 30, 2025 and July 31, 2024

In Canadian dollars

	<i>Notes</i>	30-Apr-25 \$	31-Jul-24 \$
Assets			
<i>Current assets</i>			
Cash		18,281	2,097,595
Trade and other receivables		1,314,862	1,331,903
Prepaid expenses		58,409	69,635
Inventories	4	225,062	178,035
Total current assets		<u>1,616,614</u>	<u>3,677,168</u>
<i>Non-current assets</i>			
Property, plant and equipment		2,159,607	2,392,499
Intangible assets		2	2
Total non-current assets		<u>2,159,609</u>	<u>2,392,501</u>
Total assets		<u><u>3,776,223</u></u>	<u><u>6,069,669</u></u>
Liabilities			
<i>Current liabilities</i>			
Current portion of debt	8	6,275,998	6,110,805
Trade accounts payable and accrued liabilities		2,683,916	2,716,613
Salaries and benefits payable		1,945,173	1,890,427
Interest payable		3,730,542	3,206,326
Deferred revenue		641,728	641,588
Lease liabilities	7	297,360	297,360
Provision for royalty	10	98,673	98,673
Advance from investors	11	6,032,897	5,992,335
Total current liabilities		<u>21,706,287</u>	<u>20,954,127</u>
<i>Long term liabilities</i>			
Lease liability	10	2,133,261	2,260,366
Long term portion of debt	8	1,457,187	891,781
Total long term liabilities		<u>3,590,448</u>	<u>3,152,147</u>
Total liabilities		<u>25,296,735</u>	<u>24,106,274</u>
Equity (deficiency)			
Share capital	5	68,671,091	68,671,091
Equity reserve	5	14,577,728	14,577,728
Accumulated deficit		(104,769,331)	(101,285,424)
Total shareholders' deficiency		<u>(21,520,512)</u>	<u>(18,036,605)</u>
Total liabilities and equity (deficiency)		<u>3,776,223</u>	<u>6,069,669</u>

The accompanying notes are an integral part of these consolidated financial statements.

Approved on behalf of the Board of Directors

(signed) *Hermes Chan*, Director

(signed) *Steve Cummings*, director

Unaudited consolidated statements of operations and comprehensive loss
For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

	Notes	for the three months ended		for the nine months ended	
		30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
		\$	\$	\$	\$
Revenue					
Product					
Product sales	3	59,117	75,040	189,841	200,624
Product cost of sales		(16,106)	(26,361)	(48,409)	(52,205)
Gross margin on product		<u>43,011</u>	<u>48,679</u>	<u>141,432</u>	<u>148,419</u>
Services					
Service sales	3	-	6,508	-	147,482
Service cost of sales		-	(4,882)	-	(106,826)
Gross margin on services		<u>-</u>	<u>1,626</u>	<u>-</u>	<u>40,656</u>
Operating expenses					
Research and development	13	(265,353)	(194,145)	(1,147,381)	(370,989)
Sales and marketing		(78,164)	(61,423)	(282,163)	(217,330)
Other direct costs		(192,161)	(195,100)	(632,596)	(601,682)
General and administrative		(237,098)	(202,730)	(963,400)	(711,500)
Total operating expenses		<u>(772,776)</u>	<u>(653,398)</u>	<u>(3,025,540)</u>	<u>(1,901,501)</u>
Operating loss		<u>(729,765)</u>	<u>(603,093)</u>	<u>(2,884,108)</u>	<u>(1,712,426)</u>
Non-operating income (expense)					
Financing expense	15	(253,675)	(177,054)	(740,693)	(581,958)
Government Assistance		-	-	140,894	143,088
Total non-operating income (expense)		<u>(253,675)</u>	<u>(177,054)</u>	<u>(599,799)</u>	<u>(438,870)</u>
Net and comprehensive loss		<u>(983,440)</u>	<u>(780,147)</u>	<u>(3,483,907)</u>	<u>(2,151,296)</u>
Basic loss per share	6	(0.001)	(0.001)	(0.005)	(0.003)
Diluted loss per share	6	(0.001)	(0.001)	(0.005)	(0.003)

The accompanying notes are an integral part of these consolidated financial statements.

Unaudited consolidated statements of changes in equity

In Canadian dollars

Notes	Share capital		Equity reserve \$	Accumulated deficit \$	Shareholders' deficiency \$
	Common shares	Preferred shares			
Balance at July 31, 2023	68,347,220	2,500	14,577,728	(97,959,103)	(15,031,655)
Net and comprehensive loss	-	-	-	(2,151,296)	(2,151,296)
Issuance of shares for debt	321,371	-	-	-	321,371
Balance at April 30, 2024	68,668,591	2,500	14,577,728	(100,110,399)	(16,861,580)
Net and comprehensive loss	-	-	-	(1,175,025)	(1,175,025)
Balance at July 31, 2024	68,668,591	2,500	14,577,728	(101,285,424)	(18,036,605)
Net and comprehensive income	-	-	-	(3,483,907)	(3,483,907)
Balance at April 30, 2025	68,668,591	2,500	14,577,728	(104,769,331)	(21,520,512)

The accompanying notes are an integral part of these consolidated financial statements.

Unaudited consolidated statements of cash flows
For the three months ended April 30, 2025 and April 30, 2024

In Canadian dollars

	<i>Notes</i>	30-Apr-25	30-Apr-24
		\$	\$
Cash from operating activities			
Net loss		(3,483,907)	(2,151,296)
Adjustments for:			
Depreciation		240,361	168,020
Exchange loss on conversion of debt		87,492	(5,898)
Loss on Canada Emergency Business Loan		-	20,000
Movements in working capital:			
(Increase)/decrease in trade and other receivables		17,041	(88,541)
(Increase)/decrease in inventories		(47,027)	(24,657)
(Increase)/decrease in prepaid expenses		11,226	(33,749)
(Increase)/decrease in income tax receivable		-	166,182
Increase/(decrease) in trade and other payables		(32,701)	(503,929)
Increase/(decrease) in salary and benefits payable		54,746	(21,486)
Increase/(decrease) in deferred rent		-	(1,153)
Increase/(decrease) in interest payable		524,216	411,758
Increase/(decrease) in deferred revenue		140	(111,221)
Net cash used in operating activities		<u>(2,628,413)</u>	<u>(2,175,970)</u>
Cash flow from investing activities			
Payments to acquire property, plant and equipment		(7,468)	(3,811)
Net cash used in investing activities		<u>(7,468)</u>	<u>(3,811)</u>
Cash flow from financing activities			
Increase/(decrease) in lease liability	7	(127,105)	(122,857)
Proceeds from borrowings	8	645,040	
Repayment of borrowings	8	(1,930)	-
Advances from investors	11	40,562	5,198,580
Net cash from financing activities		<u>556,567</u>	<u>5,075,723</u>
Net increase (decrease) in cash		(2,079,314)	2,895,942
Cash at the beginning of the year		2,097,595	13,178
Cash at the end of the year		<u>18,281</u>	<u>2,909,120</u>

The accompanying notes are an integral part of these consolidated financial statements.

1. Reporting entity

Nature of operations

MedMira Inc. (“MedMira” or “the Company”) is a biotechnology company headquartered in Canada. The address of the Company’s registered office is 155 Chain Lake Drive, Suite 1, Halifax, Nova Scotia, B3S 1B3. MedMira Holding AG owns the majority of MedMira’s shares and is the controlling shareholder. MedMira, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research to maintain and expand its position in the global diagnostics market. MedMira’s research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and *in vitro* sectors.

2. Basis of preparation

a. Statement of compliance

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”).

The consolidated financial statements were authorized for issue by the Board of Directors on June 30, 2025.

b. Going-concern

The accompanying consolidated financial statements have been prepared based on IFRS applicable to a going-concern, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations. However, certain adverse conditions and events cast significant doubt upon the validity of this assumption.

The Company has incurred losses and negative cash flows from operations on a cumulative basis since inception. For the nine months ended April 30, 2025, the Company realized a net loss of \$3.5 million (April 30, 2024 – net loss of \$2.1 million), consisting of a net loss from operations of \$2.9 million (April 30, 2024 – net loss of \$1.7 million), and other non-operating losses of \$0.6 million (April 30, 2024 - \$0.4million). Negative cash outflows from operations were \$2.6 million (April 30, 2024 – \$2.2 million). As of April 30, 2025, the Company had an accumulated deficit of \$104.8 million (July 31, 2024 - \$101.3 million) and a negative working capital position of \$20.1 million (July 31, 2024 - \$17.3 million). In addition, as of April 30, 2025, \$6.3 million of debt was in default. The Company currently has insufficient cash to fund its operations for the next 12 months. In addition

to its ongoing working capital requirements, the Company must secure sufficient funding for its research and development programs for existing commitments, including its current portion of debt of approximately \$6.3 million. These material uncertainties may cast significant doubt about the Company's ability to continue as a going concern.

The Company's objectives in managing capital are to ensure it can meet its ongoing working capital requirements. The Company must secure sufficient capital to support its capital requirements for research and development programs, existing commitments, including its current portion of debt of approximately \$6.3 million, as well as growth opportunities.

Management dedicates significant time to pursuing investment alternatives that will fund the Company's operations and growth opportunities so it can continue as a going concern. Debt arrangements were also ongoing with the Company's major shareholder and other debt holders. Subsequent to the close of fiscal 2025 quarter three, MedMira has generated additional revenues from product sales and a loan from a related party which support the Company's on-going operating costs and provide funding for its product development activities.

The Company is subject to risks associated with early-stage companies, including but not limited to, dependence on key individuals, competition from substitute services and larger companies, and the requirement for the continued successful development and marketing of its products and services. The Company's ability to continue as a going-concern is dependent upon its ability to generate positive cash flow from operations and secure additional financing and the continued support of its lenders and shareholders. These financial statements do not reflect the adjustments to carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going-concern assumption not appropriate. These adjustments could be material.

c. Basis of consolidation

Subsidiaries

Subsidiaries are entities controlled by the Company. Control is achieved when the Company has the power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee; and can use its power to affect its returns. The Company reassesses whether it controls an investee if facts and circumstances indicate that there changes to one or more of the three elements of control listed above. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Intra-company balances and transactions, and any unrealized income and expenses arising

from intra-company transactions, are eliminated in preparing the consolidated financial statements.

3. Revenue

The Company derives approximately 67% (April 30, 2024 – 78%) of its revenue from four (April 30, 2024 – three) main customers and, for these customers, assesses the recoverability of each account on a regular basis.

	For the three months ended		For the nine months ended	
	30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
	\$	\$	\$	\$
Product sales	59,117	75,040	189,841	200,624
Service Sales	-	6,508	-	147,482
Total Revenue	<u>59,117</u>	<u>81,548</u>	<u>189,841</u>	<u>348,106</u>

The Company organizes and records revenue based on major geographical territories around the world. The table below provides the geographic breakdown of revenue.

	Product and service revenue		Product and service revenue	
	For the three months ended		For the nine months ended	
	31-Jan-25	31-Jan-24	31-Jan-25	31-Jan-24
	\$	\$	\$	\$
North America	48,313	71,792	152,459	305,596
Europe	9,797	9,756	36,374	42,510
Other	1,007	-	1,008	-
Total Revenue	<u>59,117</u>	<u>81,548</u>	<u>189,841</u>	<u>348,106</u>

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

*For the nine months ended April 30, 2025, revenue in North America included sales made in Canada (the Company's country of domicile) of \$42,050 (April 30, 2024 - \$19,615).

4. Inventories

As of April 30, 2025, there were no valuation allowances against inventory (July 31, 2024 - \$nil).

During the three months ended April 30, 2025, inventory valued at \$37,502 was expensed as product cost of sales (April 30, 2024 - \$48,129,) which included write-downs of inventory because of net realizable value being lower than cost of \$712 (April 30, 2024 – \$15,430). No inventory write-downs recognized in previous years were reversed during the current year.

	30-Apr-25	31-Jul-24
	\$	\$
Raw materials and consumables	206,510	169,015
Work in progress	212	-
Finished goods	18,340	9,020
Total Inventories	225,062	178,035

5. Capital and other components of equity

a. Authorized

The Company is authorized to issue an unlimited number of Series A preferred shares, non-voting, non-participating, redeemable at the Company's option at \$0.001 per share after March 31, 2010, convertible into an equal number of common shares upon the Company meeting certain milestones. The preferred shares earn no dividends.

The Company is authorized to issue an unlimited number of voting common shares without nominal or par value.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

b. Share capital issued

The total common shares issued and outstanding includes 4,064,464 common shares held in escrow scheduled to be released when the Company obtains positive operating cash flow.

	Number of		Value of		
	Common Shares	Preferred Shares	Common shares	Preferred shares	Total share capital
			\$	\$	\$
Balance at July 31, 2024	701,730,591	5,000,000	68,668,591	2,500	68,671,091
Balance at April 30, 2025	701,730,591	5,000,000	68,668,591	2,500	68,671,091

The Series A preferred shares had a stated capital of \$2,500 on April 30, 2025 (July 31, 2024 - \$2,500).

c. Equity Reserve

The change in equity reserve is outlined in the table below:

	<u>Equity Reserve</u>
	\$
Balance at July 31, 2024	14,577,728
Balance at April 30, 2025	14,577,728

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

6. Loss per share

	for the three months ended		for the nine months ended	
	30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
Net income (loss)	(983,440)	(780,147)	(3,483,907)	(2,151,296)
Issued common shares	701,730,591	701,730,591	701,730,591	701,730,591
Weighted average number of common shares	701,730,591	698,088,400	701,730,591	698,088,400
Basic earnings (loss) per share	(0.001)	(0.001)	(0.005)	(0.003)
Diluted earnings (loss) per share	(0.001)	(0.001)	(0.005)	(0.003)

The diluted weighted average number of common shares outstanding is the same as the basic weighted average number of common shares outstanding for the three months ended April 30, 2025, as the exercise of options would be anti-dilutive.

7. Lease liability

	Building \$
Balance at July 31, 2024	2,557,726
Interest expense	95,915
Less: lease payments	(223,020)
Balance at April 30, 2025	2,430,621
Less: current portion	(297,360)
	2,133,261

The lease liability is based on one lease the company has for the building it is using for operations. The remaining lease term is 12 years. The imputed finance costs of the liability were determined

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

based on an incremental borrowing rate of 5%. The minimum lease payments for the next five year are as follows:

	Lease liability	Finance charge	Total
	\$	\$	\$
May 2025 to April 2026	175,829	121,531	297,360
May 2026 to April 2027	188,654	112,740	301,394
May 2027 to April 2028	200,118	103,301	303,419
May 2028 to April 2029	210,109	224,649	434,758
May 2029 to April 2030	224,649	82,796	307,445

8. Loans and borrowings

a. Loans

	30-Apr-25		31-Jul-24	
	Carrying value	Contract value	Carrying value	Contract value
	\$	\$	\$	\$
Short term loans	180,429	180,429	163,598	163,598
Loan 1	1,054,167	1,054,167	1,054,167	1,054,167
Loan 2	1,300,000	1,300,000	1,300,000	1,300,000
Loan 3	4,402	4,402	6,038	6,038
Loan 4	335,600	335,600	314,040	314,040
Loan 5	184,580	184,580	172,722	172,722
Loan 6	167,800	167,800	157,020	157,020
Loan 7	150,000	150,000	150,000	150,000
Loan 8	38,246	38,246	38,240	38,240
Loan 9	671,200	671,200		
Canada emergency business account	59,761	59,761	59,761	59,761
ACOA loans	473,610	473,610	473,610	473,610
Nova Scotia government loan 1	3,016,000	3,016,000	3,016,000	3,016,000
Nova Scotia government loan 2	97,390	97,390	97,390	97,390
Total loan principal	<u>7,733,185</u>	<u>7,733,185</u>	<u>7,002,586</u>	<u>7,002,586</u>
Long term portion of principal	1,457,187		891,781	
Current portion payable or principal	6,275,998		6,110,805	

The required annual principal repayments on loans and borrowings are as follows:

2025	6,275,998
2026	-
2027	785,987
2028	671,200
Carrying value	<u>7,733,185</u>

Short term loans

The Company has various short-term loans with one related party. These loans were utilized by the Company for short-term working capital requirements. The loans have an interest rate of 5% per year. As of April 30, 2025, the loans are all in default due to non-payment.

Loan 1

Loan established October 31, 2012, bearing 5% interest with monthly interest only payments until November 30, 2013, followed by monthly principal payments and accrued interest for five additional years ending November 30, 2018. The loan is secured by interest on intellectual property and on the step-up technology. The loan was in default as of April 30, 2025, due to nonpayment of interest and principal payments and thus has been classified as a current liability.

Loan 2

Loan established July 31, 2012, bearing 5% interest with monthly interest payments were due until April 30, 2016, followed by equal monthly principal payments and accrued interest for four additional years ending July 31, 2022. The loan was in default due to nonpayment of interest and principal payments as of April 30, 2025, and thus has been classified as a current liability.

Loan 3

Loan was established on July 31, 2016, bearing 5% interest with the Company's Chief Financial Officer. The loan was renegotiated on January 21, 2017, and is now fully payable on or before October 1, 2018. The loan was in default due to nonpayment of interest and principal payments as of April 30, 2025 and thus has been classified as a current liability.

Loan 4

Loan was established on December 19, 2022, with a shareholder. The loan bears 5% interest and is due on August 1, 2026.

Loan 5

Loan was established on February 27, 2023, with a shareholder. The loan bears 5% interest and is due on December 1, 2026.

Loan 6

Loan was established on April 4, 2023, with a member of the board of directions. The loan bears 5% interest and is due on originally due on August 18, 2025. The loan has been extended to August 18, 2026.

Loan 7

Loan was established on August 18, 2022. The loan bears 5% interest and is due on August 18, 2025.

Loan 8

Loan was established on August 18, 2022. The loan bears 5% interest and was originally due on August 18, 2025. The loan has been extended to August 18, 2026.

Loan 9

Loan was established on March 3, 2025 with a related party. The loan bears 5% interest and is due on April 30, 2028.

Canada Emergency Business Account (CEBA)

The Company received a loan of CAD\$60,000 from Bank of Montreal which is fully secured by the Government of Canada. This Relief Line of Credit was the governments direct response to support Canadian companies during the COVID-19 situation. The loan is due in full on December 31, 2026 and carries an interest rate of 5%. The company did not repay the before January 18, 2024, therefore the Company has forfeited its entitlement to a credit in the amount of 33.3% equal to \$20,000.

Atlantic Canada Opportunities Agency (ACOA) loans

Loans established on October 31, 2012, bearing no interest with monthly principal payments of \$3,747 until July 31, 2013, followed by monthly principal payments of \$24,234 for five additional years ending July 31, 2018. The loan was renegotiated in July 2014, bearing no interest with a monthly principal payment of \$24,234 in August 2014 followed by 40 monthly principal payments of \$27,800 starting on February 1, 2015, and one monthly principal payment of \$26,975 at the end of the loan. The loan is secured by all present and subsequently acquired personal property,

excepting consumer goods. The loan was in default on April 30, 2025, due to non-payment of principal and interest and thus has been classified as a current liability.

Nova Scotia government loan 1

The loan was established in August 2015, bearing interest based on the Province of Nova Scotia's five-year cost of funds, plus five hundred basis points. Monthly interest payments are due until August 31, 2018. Starting on September 1, 2016, thirteen monthly principal payments of \$120,000 are due followed by ten monthly principal payments of \$135,000 starting on October 1, 2017, and one monthly principal payment of \$106,000 on August 1, 2018. The loan is secured by first interest on intellectual property and on the Maple Bio sensor technology. The loan was in default due to nonpayment of interest and principal payments on July 31, 2024, and thus has been classified as a current liability. In September 15, 2020, the Company has entered into a forbearance agreement with the Province of Nova Scotia which allows the Company to defer principal and interest payments. The terms and condition were based on the Company's growth and milestone-based achievements. On March 9, 2023, the Company received an additional Forbearance extension for a period of twelve months. On April 3, 2024, the Company received an additional Forbearance extension for a period of twelve months. Pending on the Company's achievement of growth milestones, the Province may extend this further.

Nova Scotia government loan 2

Loan established September 14, 2012, bearing no interest with the balance due by August 31, 2018. The loan is secured by first interest on intellectual property and on the Maple Bio sensor technology. The loan was in default due to nonpayment of interest and principal payments on July 31, 2023, and thus has been classified as a current liability. On September 15, 2020, the Company has entered into a forbearance agreement with the Province of Nova Scotia which allows the Company to defer principal and interest payments. The terms and condition were based on the Company's growth and milestone-based achievements. On April 3, 2024, the Company received an additional Forbearance extension for a period of twelve months. Pending on the Company's achievement of growth milestones, the Province may extend this further.

9. Capital management and financial risks

a. Capital management

The Company's objectives in managing capital are to ensure sufficient liquidity to support the capital requirements of its various businesses, including growth opportunities. As of the date of these

statements, the Company does not have sufficient liquidity to meet all its obligations. The Company manages its capital structure and adjusts considering general economic conditions, the risk characteristics of the underlying assets and the Company's working capital requirements. Management of the capital structure involves the issuance of new debt, the repayment of existing debt using cash generated by operations and issuance of additional financial structures such as product financing and royalty agreements. There is no assurance that the Company will be able to raise funds in the future to fund its operations. The capital structure of the Company is composed of shareholders' deficiency, cash, long-term and short-term debts. The provisions of certain financing agreements provide for restrictions on the activities of the Company in terms of their use of funds. Such restrictions are mainly applied in specific product development financing projects. The Company's objectives when managing capital are to provide competitive cost structures, safeguard its assets and daily cash flow management to maximize the Company's cash holding.

The Company's capital is summarized in the table below.

	30-Apr-25	31-Jul-24
	\$	\$
Total debt	7,733,185	7,002,586
Less: Cash	(18,281)	(2,097,595)
Net debt	7,714,904	4,904,991
Shareholders' deficiency	(21,520,512)	(18,036,605)
Total capital	(13,805,608)	(13,131,614)

Refer to the note 2b for information on how the Company manages its plan and its ability to continue as a going concern.

b. Foreign currency risk

Most of the Company's sales are denominated in foreign currencies. The Company's US dollar foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are shown in the table below.

	30-Apr-25	31-Jul-24
	US \$	US \$
Cash	6,496	30,612
Trade and other receivables	900,343	915,620
Prepaid expenses	267	2,222
Accounts payable and accrued liabilities	1,350,362	1,300,993
Royalty provision	71,455	71,455
Advances from investors	1,669,168	1,647,668
Debt	27,690	27,690

A one percent change in the US dollar exchange rate would result in approximately a \$40,258 (July 31, 2024 - \$39,963) impact on the statement of financial position and consolidated statement of operations.

The Company's Swiss Franc foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are shown in the table below:

	30-Apr-25	31-Jul-24
	CHF	CHF
Cash	777	120
Trade and other receivables	2,048	2,048
Prepaid expenses	17,903	17,903
Accounts payable and accrued liabilities	390,224	379,825
Advances from investors	96,211	96,211
Debt	916,813	518,036

A one percent change in the CHF dollar exchange rate would result in approximately a \$14,240 (July 31, 2024 - \$10,141) impact on the statement of financial position and consolidated statement of operations.

c. Interest rate risk

The Company is not exposed to interest rate risk as it borrows funds at fixed rates.

d. Credit risk

The Company exposed to credit risk in relation to its trade accounts receivable. To mitigate such risk, the Corporation continuously monitors the financial condition of its customers and reviews the credit history or worthiness of each new customer. The Company mitigates this risk by requiring a 100% down payment with customers who are unknown to them and may pose a credit risk prior to shipment for new clients. The Company establishes an allowance for doubtful accounts based on specific credit risk of its customers by examining such factors as the number of overdue days of the customers' balance outstanding as well as the customers' collection history.

Trade and other receivables include amounts that are past due as of April 30, 2025, for which the Company has not recognized an allowance for doubtful accounts because there has not been a significant change in the credit quality of the customer and the amounts are still considered recoverable.

e. Liquidity risk

Liquidity risk represents the possibility that the Company may not be able to gather sufficient cash resources, when required and under reasonable conditions, to meet its financial obligations. As of April 30, 2025, the Company does not have sufficient cash to meet all its current liabilities. As shown in note 8, the company is in default of loans in the amount of \$6,275,998.

The Company also continues to have an ongoing need for substantial capital resources to research and develop, commercialize, and manufacture its products and technologies. The Company is not yet receiving a significant ongoing revenue stream, nor can it be certain that it will receive significant revenue before additional cash is required. As a result, there can be no assurance that the Company will have sufficient capital to fund its ongoing operations, develop or commercialize its products without future financing.

The Company's contractual maturities for its financial liabilities are outlined in the table below.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

For the nine months ended April 30, 2025

	Total	Less than 1 year	1 to 3 years	4 to 5 years	After five years
	\$	\$	\$	\$	\$
Debt	7,733,185	6,275,998	1,457,187	-	-
Accounts payable and accrued liabilities	8,359,631	8,359,631	-	-	-
Lease liabilities	2,430,621	175,829	388,764	434,758	1,431,270
Advance from investors	6,032,897	6,032,897	-	-	-
Royalty provision	98,673	98,673	-	-	-
Total debt	24,655,007	20,943,028	1,845,951	434,758	1,431,270

For the year ended July 31, 2024

	Total	Less than 1 year	1 to 3 years	4 to 5 years	After five years
	\$	\$	\$	\$	\$
Debt	7,002,586	6,110,805	891,781	-	-
Accounts payable and accrued liabilities	7,813,366	7,813,366	-	-	-
Lease liabilities	2,557,726	169,473	370,338	415,156	1,602,759
Advance from investors	5,992,335	5,992,335	-	-	-
Royalty provision	98,673	98,673	-	-	-
Total debt	23,464,686	20,184,652	1,262,119	415,156	1,602,759

The payments noted above do not include interest payments.

10. Royalty provision

During March 2015, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future US sales of the Reveal G4 product for a five-year period commencing on the day the first full payment and delivery of at least CAD \$100,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$270,000 to fund costs required to complete the product development and obtain US Food and Drug Administration (FDA) pre-market approval. At the inception of the arrangement, the Company's best estimate of the value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$270,000 was recorded in equity (Note 8). As of April 30, 2025, the Company's best estimate of the fair value of the provision was \$98,673 (July 31, 2024 - \$98,673), which is recorded in royalty provision and the change in fair value of the provision recorded in financing expense in profit or loss.

During July 2016, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future sales of the hepatitis C (HCV) portion of the approved Multiplo HIV/HCV test commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$200,000 to fund costs required to complete product development and

obtain FDA pre-market approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$200,000 was recorded in equity reserve. As of April 30, 2025, the Company's best estimate of the fair value of the provision was zero. Management's fair value estimate was based on changes made during the FY2017 product commercialization prioritization process which placed the Multiplo HIV/HCV project on hold until further notice.

During October 2016, the Company entered into a royalty agreement with Ritec AG whereby Ritec AG would receive a 12.5% royalty on all future sales of the approved Reveal G4 CLIA-waived product commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, Ritec AG provided the Company with \$1,310,100 to fund costs required to complete the product development, clinical trials and obtain FDA approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as Ritec AG is owned by a shareholder of MedMira Holding AG who is the controlling shareholder of the Company, the \$1,310,100 was recorded in equity reserve. On April 30, 2025, the Company's best estimate of the fair value of the provision was zero.

The change in royalty provision is outlined in the table below:

11. Advances from investors

During the three months ended April 30, 2025, the Company has received \$29,780 (fiscal year 2024 - \$3,000,000) in advances from investors. These advances will be converted to common shares at a date to be determined. Until such time that the advances are converted to common shares, the company is obligated to pay 5% interest on the amount received.

12. Related parties

The following transactions occurred with related parties during the nine months ended April 30, 2025:

- A long-term loan of \$671,200 was received from a shareholder (2024 – nil).
- A short-term loan of \$5,600 was received from the Chief Financial Officer (2024 – nil).
- Advances from investors of nil were received (2024 - \$3,669,850).

The following balances with related parties were outstanding on April 30, 2025:

- Salaries and benefits totalling \$1,454,979 were due to the CEO and CFO (July 31, 2024 - \$1,383,556).
- A long-term loan totalling \$4,402 (July 31, 2024 - \$6,038) and accrued interest of \$63 (2024 - \$76) was due to the Chief Financial Officer.
- A royalty provision was owed to MedMira Holding AG of \$98,673 (July 31, 2024 - \$98,673).
- Short term loans totalling \$180,432 (July 31, 2024 - \$163,598) and accrued interest of \$2,527 (2024 - \$9,014) were owed to one officer.
- Long term loans totalling \$1,191,380 (July 31, 2024 - \$486,762) and accrued interest of \$65,058 (2024 - \$37,684) were owed to a shareholder.
- A long-term loan totalling \$167,800 (July 31, 2024 - \$157,020) and accrued interest of \$17,401 (2024 - \$10,411) was owed to a member of the board of directors.
- Shareholder advances totalling \$3,690,600 (July 31, 2024 - \$3,690,450) and accrued interest of \$223,318 (2024 - \$85,292) were owed to the company's largest shareholder.
- Expenses in the amount of \$18,230 (July 31, 2024 - \$17,059) were owed to an officer.

13. Research and development

The following table provides a summary of aggregate research costs and reimbursements.

	for the three months ended		for the nine months ended	
	30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
Research and development expenses	\$ (265,353)	\$ (199,028)	\$ (1,147,381)	\$ (440,823)
Less: research and development expenses allocated to cost of sales	-	4,883	-	69,834
Net research and development expense	(265,353)	(194,145)	(1,147,381)	(370,989)

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2025 and April 30, 2024

In Canadian dollars

14. Expenses by nature

The following table provides the Company's expenses listed by the nature of the expense.

	for the three months ended		for the nine months ended	
	30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
	\$	\$	\$	\$
Change in inventory	(13,337)	(25,430)	(37,501)	(48,128)
Employee benefits	(380,561)	(352,357)	(1,127,373)	(1,060,398)
Depreciation	(80,085)	(55,200)	(240,361)	(168,020)
Distribution	(143)	(6,008)	(14,959)	(24,705)
Facility	(45,331)	(56,425)	(123,093)	(117,710)
Professional services	(254,754)	(106,454)	(1,197,919)	(361,627)
Lab supplies	(7,455)	(64,701)	(48,364)	(82,736)
Other expenses	(31,864)	(71,786)	(146,581)	(196,344)
Exchange gains/(losses)	24,648	53,720	(137,798)	(864)
Government assistance	-	-	140,894	143,088
Finance Costs	(253,675)	(177,054)	(740,693)	(581,958)
	<u>(1,042,557)</u>	<u>(861,695)</u>	<u>(3,673,748)</u>	<u>(2,499,402)</u>

15. Financing expense

A breakdown of the income (expenses) allocated to financing expense on the consolidated statements of operations and comprehensive loss is provided in the table below.

	for the three months ended		for the nine months ended	
	30-Apr-25	30-Apr-24	30-Apr-25	30-Apr-24
	\$	\$	\$	\$
Finance costs	(253,675)	(177,054)	(740,693)	(581,958)
Total financing expense	<u>(253,675)</u>	<u>(177,054)</u>	<u>(740,693)</u>	<u>(581,958)</u>

16. Subsequent events

Subsequent to the end of the quarter, the company received a loan from a shareholder in the amount of CHF 315,000. This loan has an annual interest rate of 5% and is due on April 30, 2028.